Infekcinių ligų ir patogeninės mikrobiologijos institutas, VšĮ - financials and debts

Company age: 9 y. 10 mo.

Update

Infekcinių ligų ir patogeninės mikrobiologijos institutas - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue - 59,199 42,753 93,436 163,223 104,438 238,417 27,148
Profit before tax - - - - 17,404 -570 95,905 -72,048
Net profit - - - - 17,404 -570 95,905 -72,048
Equity 5,388 9,325 3,903 33,721 51,125 50,555 146,460 74,412
Liabilities 387 1,152 3,779 407 5,409 5,346 19,583 11,534
Non-current assets 0 996 644 6,369 6,924 20,014 19,536 32,079
Current assets 5,775 9,481 49,283 44,188 49,610 35,887 146,507 53,867
Total assets 5,775 10,477 49,927 50,557 56,534 55,901 166,043 85,946
Taxes paid
STI taxes - - - - - 8,127 8,038 7,846
Financial indicators
Revenue change y/y - - -27.8% +118.5% +74.7% -36.0% +128.3% -88.6%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. - - - - 30.8% -1.0% 57.8% -83.8%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. - - - - 34.0% -1.1% 65.5% -96.8%
Profit margin Net profit margin. Shows the overall profitability of the company. - - - - 10.7% -0.5% 40.2% -265.4%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. - - - - 10.7% -0.5% 40.2% -265.4%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 0.1 0.1 1.0 0.0 0.1 0.1 0.1 0.2
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. - 22,199 16,032 23,359 46,635 34,813 79,472 9,049

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

Sales revenue

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Infekcinių ligų ir patogeninės mikrobiologijos institutas - Social security debts

From To Debt, €
2026-09-05 2026-09-05 0.67
2026-08-26 2026-09-02 0.67
2026-08-23 2026-08-23 0.67
2026-08-19 2026-08-19 0.67
2026-07-23 2026-08-02 0.67
2026-05-17 2026-05-17 824.10
2023-08-17 2023-08-23 0.74
2023-07-24 2023-08-06 0.74
2023-04-18 2023-04-19 821.45

Infekcinių ligų ir patogeninės mikrobiologijos institutas - VMI tax arrears

From To Overdue, €
2026-05-13 2026-05-18 19.84

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Infekciniu ligu ir patogenines mikrobiologijos institutas, VšI (code 304426986), is a Public Institution engaged in research and development in medical sciences. In 2025, revenue fell to €27.1K from €238.4K in 2024 and €104.4K in 2023, while net profit turned into a €72.0K loss after a €95.9K profit in 2024 and a small €570 loss in 2023. The 2025 result was marked by a sharply negative margin, reflecting the weak revenue base and higher costs relative to turnover. At year-end 2025, total assets were €85.9K, equity €74.4K and liabilities €11.5K; equity remained the main funding source, with an equity ratio of 86.6% and debt-to-equity of 0.16. Long-term assets stood at €32.1K and short-term assets at €53.9K. Asset turnover was 0.32x. Revenue per employee was €9.0K and profit per employee was -€24.0K. Overall, the company moved from strong profitability in 2024 to a substantial loss in 2025.